magnolol has been researched along with Multiple Sclerosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ali, H; Bibi, T; Khan, A; Khan, AU; Khan, S; Seo, EK; Shal, B | 1 |
| Chen, JY; Chen, LD; Chen, LL; Huang, MQ; Ma, XQ; Nan, LH; Pan, RR; Tian, XY; Wang, QQ; Wei, SS; Xu, W | 1 |
2 other study(ies) available for magnolol and Multiple Sclerosis
| Article | Year |
|---|---|
Magnolol prevented brain injury through the modulation of Nrf2-dependent oxidative stress and apoptosis in PLP-induced mouse model of multiple sclerosis.
Topics: Animals; Antioxidants; Apoptosis; Biphenyl Compounds; Brain Injuries; Caspase 3; CD8-Positive T-Lymphocytes; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Female; Lignans; Mice; Molecular Docking Simulation; Multiple Sclerosis; NF-E2-Related Factor 2; Oxidative Stress | 2022 |
Magnolol as STAT3 inhibitor for treating multiple sclerosis by restricting Th17 cells.
Topics: Animals; CD8-Positive T-Lymphocytes; Cell Differentiation; Cytokines; Encephalomyelitis, Autoimmune, Experimental; Interleukin-17; Mice; Mice, Inbred C57BL; Molecular Docking Simulation; Multiple Sclerosis; STAT3 Transcription Factor; Th1 Cells; Th17 Cells | 2023 |